Aripiprazole/sertraline (developmental code name ASC-01) is a combination formulation of aripiprazole (Abilify), an atypical antipsychotic, and sertraline (Zoloft), a selective serotonin reuptake inhibitor (SSRI), which was under development by Otsuka Pharmaceutical for the treatment of major depressive disorder (MDD).[1] It combines serotonin reuptake inhibition from sertraline and modulation of dopamine and serotonin receptors from aripiprazole.[1][2] In July 2017, it was in preregistration in Japan for the treatment of MDD.[1] However, in September 2018, the regulatory submission in Japan for MDD was withdrawn.[3]
| Combination of | |
|---|---|
| Aripiprazole | Atypical antipsychotic |
| Sertraline | Selective serotonin reuptake inhibitor |
| Clinical data | |
| Other names | ASC-01 |
| Routes of administration | By mouth |
| Legal status | |
| Legal status | |
See also
editReferences
edit- ^ a b c "Aripiprazole/sertraline - Otsuka Pharmaceutical". AdisInsight. Springer Nature Switzerland AG.
- ^ Kamdijima K, Kimura M, Kuwahara K, Kitayama Y, Tadori Y (August 2018). "Randomized, double-blind comparison of aripiprazole/sertraline combination and placebo/sertraline combination in patients with major depressive disorder". Psychiatry and Clinical Neurosciences. 72 (8): 591–601. doi:10.1111/pcn.12663. PMID 29660207. S2CID 4958169.
- ^ "Aripiprazole/sertraline - Otsuka Pharmaceutical - AdisInsight". adisinsight.springer.com.
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |